Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days?

The optimal dose and duration of rabbit antithymocyte globulin (rATG) induction has not been defined. Methods. We compared the safety and efficacy of 2 dosing strategies, rATG 1.5 mg/kg for 4 days (n = 59) versus 2 mg/kg for 3 days (n = 59), in a retrospective, cohort study. Results. Two-year rejection-free survival was 95% in each group (P = .983). Renal function and infection rates were similar. The incidence of leucopenia was similar, although the 2 mg/kg group was more likely to be thrombocytopenic on day 2 (4% versus 28%, P = .04). Length of stay tended to be longer for the 1.5 mg/kg group (6.0 ± 3.7 versus 5.1 ± 1.9 days P = .104). A cost savings of $920 per patient for rATG were seen in the 2 mg/kg group (P = .122). Conclusions. Shorter, more intense dosing of rATG is safe and effective. The 3-day dose strategy resulted in a clinically shorter length of stay and may result in cost savings.

[1]  C. Drachenberg,et al.  Thymoglobulin Dose Optimization for Induction Therapy in High Risk Kidney Transplant Recipients , 2008, Transplantation.

[2]  A. Langnas,et al.  Randomized Trial of Single-Dose Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation: An Interim Report , 2008, Transplantation.

[3]  W. Winkelmayer,et al.  Comparison of two dosages of thymoglobulin used as a short‐course for induction in kidney transplantation , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  Tutut Herawan,et al.  Computational and mathematical methods in medicine. , 2006, Computational and mathematical methods in medicine.

[5]  R. Stratta,et al.  Experience with alternate-day thymoglobulin induction in pancreas transplantation with portal-enteric drainage. , 2005, Transplantation proceedings.

[6]  F. Delmonico,et al.  A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1 , 2003, Transplantation.

[7]  Paulo Fontes,et al.  Tolerogenic immunosuppression for organ transplantation , 2003, The Lancet.

[8]  E. Woodle,et al.  Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on cd3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients , 2002, Transplantation.

[9]  T. Howard,et al.  Short course induction immunosuppression with thymoglobulin for renal transplant recipients. , 2002, Transplantation.

[10]  J. Revillard,et al.  MECHANISMS INVOLVED IN ANTITHYMOCYTE GLOBULIN IMMUNOSUPPRESSIVE ACTIVITY IN A NONHUMAN PRIMATE MODEL 1 , 2001, Transplantation.

[11]  M. Schnitzler,et al.  A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. , 1999, Transplantation.

[12]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[13]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[14]  K. Lamborn,et al.  Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. , 1998, Transplantation.

[15]  M. Schnitzler,et al.  Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. , 1997, Transplantation.

[16]  T. Howard,et al.  Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. , 1997, Journal of the American Society of Nephrology : JASN.

[17]  Robert Kerchner,et al.  Interim Report , 1996 .